Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Maravai LifeSciences Holdings, Inc. - Class A common stock (NQ:MRVI)

2.045 -0.055 (-2.62%)
Streaming Delayed Price Updated: 9:33 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Maravai LifeSciences Holdings, Inc. - Class A common stock

< Previous 1 2 3 4 5 6 7 Next >
MARAVAI ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Maravai LifeSciences Holdings, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MRVI ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Maravai Lifesciences Holdings, Inc. Investors
From Kirby McInerney LLP
Via Business Wire
Rosen Law Firm Urges Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences
From Faruqi & Faruqi LLP
Via GlobeNewswire
Law Offices of Howard G. Smith Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
MRVI CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Maravai LifeSciences Holdings, Inc.
From The Law Offices of Frank R. Cruz
Via Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences
From Faruqi & Faruqi, LLP
Via Business Wire
MRVI Class Action Notice: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Maravai LifeSciences Holdings, Inc. Investors
From Glancy Prongay & Murray LLP
Via Business Wire
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Maravai Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MRVI INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Maravai LifeSciences Holdings, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Securities Fraud Investigation Into Maravai LifeSciences Holdings, Inc. (MRVI) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Maravai LifeSciences Securities Fraud Investigation: Investors Urged to Contact Award-Winning Firm, Gibbs Law Group LLP
From Gibbs Law Group
Via Business Wire
Maravai LifeSciences Holdings, Inc. (MRVI) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Maravai LifeSciences Holdings, Inc. (MRVI) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio
From TriLink BioTechnologies
Via Business Wire
TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
From TriLink BioTechnologies
Via Business Wire
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies
From Maravai LifeSciences, Inc.
Via Business Wire
Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue
Announces Earnings Release Date 
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
Carl Hull to Retire as Executive Chairman 
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciences Announces November 2024 Investor Conference Schedule
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research
From Maravai LifeSciences, Inc.
Via Business Wire
Maravai LifeSciences Reports Third Quarter 2024 Financial Results
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase
From TriLink BioTechnologies
Via Business Wire
Cygnus Technologies and TriLink BioTechnologies® Collaborate to Launch AccuRes™ Host Cell DNA Quantification Kits
From TriLink BioTechnologies
Via Business Wire
Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciences Reports Second Quarter 2024 Financial Results
Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation 
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciences Appoints Trey Martin to Board of Directors
Maravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experience 
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.